Clinical Trials in Baltimore

Showing 7061-7080 of 17,842 trials

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

NCT04720664

This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer. It is designed to determine efficacy, defined as the objective response rate (ORR) of this investigational treatment. It is hypothesized that SM-88 used with MPS will lead to significant anti-tumor responses with acceptable toxicities in patients with metastatic HR+/HER2- breast cancer.

Breast CancerMetastatic Breast CancerHormone Receptor Positive Breast Carcinoma

Georgetown University11 participantsStarted Sep 2021

Washington D.C., District of Columbia, United States • Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States +2 more locations

COMPLETEDPhase 1< 1 mile

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

NCT03955666

This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects

Safety

Provention Bio, Inc.16 participantsStarted Aug 2019

Baltimore, Maryland, United States

TERMINATEDPhase 226 miles

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more

Mirati Therapeutics Inc.260 participantsStarted Sep 2018

Tucson, Arizona, United States • Irvine, California, United States • Aurora, Colorado, United States +33 more locations

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Find Trials by Condition in Baltimore

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Investigation of Novel Surgical Imaging for Tumor Excision

BioVentrix Revivent TC™ System Clinical Study

Study of Sargramostim in Patients With COVID-19

Maximizing Outcomes in Treating Acute Migraine

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence

Safety and Tolerability of Repeat Courses of IM Alefacept

A Dose Finding Study to Treat Bone Tumor(s)

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Resynchronization/Defibrillation for Ambulatory Heart Failure Trial

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome